LEXINGTON, Mass.--(BUSINESS WIRE)--March 7, 2006--Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced that it has filed a New Patent Application with the U.S. Patent Office covering the use of pagoclone as a treatment for premature ejaculation (PE). The patent filing is based on evidence of pharmacologic activity contained in the Company’s existing clinical databases.
